Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.

With yet another quarter where Pfizer handily beat consensus earnings expectations, it’s even more clear that CEO Albert Bourla is already well on his way toward getting Pfizer back on track ...

antibody-based therapeutic candidates in solid tumors and advancements in our emerging pre-clinical pipeline,” said Zymeworks CEO Kenneth Galbraith. The Aspect Biosystems’ cash infusion is ...

The continued soaring success of Keytruda speaks to the triumphant legacy of Merck’s former CEO, the legendary Ken Frazier, who delivered countless blockbusters during his tenure at the top from which ...

The continued soaring success of Keytruda speaks to the triumphant legacy of Merck’s former CEO, the legendary Ken Frazier, who delivered countless blockbusters during his tenure at the top from ...

Before that, she spent the better part of two decades at EMD Serono, Merck KGaA’s U.S. pharma subsidiary ... M.D., Moderna’s president, and CEO Stephane Bancel. More recently, Moderna has ...

The newspaper reported that Kenneth Bresnahan, the Detroit investigator that Frazier reportedly admitted Brown's murder to, called Frazier the "most vicious person" he had ever come across.

As the nation kicks off Black History Month, a look into the industry shows there is a significant lack of Black leaders.

Merck CEO Robert Davis said on an earnings call that Gardasil inventory in China "remains elevated at above normal levels," noting that demand for the shot has not recovered to the level the ...